Linking interferon to antibodies to fight tumors
This article was originally published in Start Up
Interferon has proved helpful in treating many diseases, but its usefulness has always been limited by side effects that arise from the drug's inherent ability to stimulate the immune system. Start-up ImmunGene Inc. thinks it has figured out a way to engineer interferon so that it has little potency unless and until the protein binds to a tumor, only then displaying an active form of interferon capable of provoking inflammation and triggering cell death.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.